Buy Rating Affirmed for Passage Bio on Strong Cost Control and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)
Positive Outlook for Passage Bio: Strategic Financial Moves and Promising Clinical Prospects Boost Buy Rating
Expanding Market and Promising Preclinical Results Bolster Buy Rating for Passage Bio
Passage Bio Analyst Ratings
Optimistic Outlook for Passage Bio Amid Clinical and Financial Progress: Maintains Buy Rating
Passage Bio (PASG) Gets a Buy From TD Cowen
Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
Passage Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), OrganiGram Holdings (OGI) and Passage Bio (PASG)
Passage Bio Earns Buy Rating Based on Robust Financial Position and Promising AAV1-based GT PBFT02 Trial
Raymond James Maintains Outperform on Passage Bio, Lowers Price Target to $5
Passage Bio Analyst Ratings
Wedbush Lowers Passage Bio's Price Target to $3 From $5, Maintains Outperform Rating
Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9
Passage Bio Analyst Ratings
Passage Bio (PASG) Gets a Buy From Chardan Capital
Raymond James Trims Price Target on Passage Bio to $9 From $10, Keeps Outperform Rating
Raymond James Maintains Outperform on Passage Bio, Lowers Price Target to $9
No Data